about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Mallinck­rodt's woes per­sist as re­for­mu­lat­ed opi­oid painkiller fails to pass FDA muster

7 years ago
R&D

Bausch is keen on Syn­er­gy, af­ter trou­bled con­sti­pa­tion drug mak­er files for Chap­ter 11

7 years ago
Pharma

Am­gen en­lists En­tera in a drug dis­cov­ery pact; Boehringer brings out the bud­get ax

7 years ago
News Briefing

Large coali­tion joins drug lob­by in de­nounc­ing Trump pro­pos­al to im­port drug prices for Medicare

7 years ago
Pharma

Tar­get­ing CD47? UCLA joins band­wag­on, with gel to stem tu­mors from resur­fac­ing

7 years ago
Discovery

Shang­hai Jun­shi Bio­sciences next to test HKEX list­ing; With one eye on Sage, Mar­i­nus re­ports pre­lim PPD da­ta

7 years ago
News Briefing

As­traZeneca, Can­cer Re­search UK set up ge­nomics hub to fight up­hill bat­tle against can­cer

7 years ago
R&D
Discovery

Sanofi will elim­i­nate 670 jobs in France; Mod­er­na gets FDA or­phan sta­tus for pre­clin­i­cal as­set

7 years ago
News Briefing

De­lay brings suc­cess for Roche as it fi­nal­ly wins FDA nod for Tecen­triq reg­i­men in front­line lung can­cer

7 years ago
Pharma

As­traZeneca's prized Imfinzi/treme­li­mum­ab com­bo fails again — this time in head and neck can­cer

7 years ago
R&D

Mallinck­rodt to spin off gener­ics busi­ness; Be­yond­Spring ready to sub­mit ap­proval for lead drug in Chi­na

7 years ago
News Briefing

In search of biotech hub glo­ry, the Big Ap­ple lures lo­cal star­tups with lab space

7 years ago
Pharma

Su­per­nus touts AD­HD Phase III da­ta, but re­sults ap­pear to fall short of ex­pec­ta­tions

7 years ago
R&D

While we wait for NASH da­ta, Gen­fit re­ports pos­i­tive elafi­bra­nor da­ta in PBC pa­tients

7 years ago
R&D

UK sets up vac­cines cen­tre as Brex­it looms; Shang­hai's Elpi­science bags $35M in Se­ries B

7 years ago
News Briefing

A last-ditch ef­fort to de­rail Take­da’s $62B Shire buy­out goes down in flames

7 years ago
Deals
Pharma

Gilead­'s HIV drug De­scovy wins Chi­na's en­dorse­ment; Re­vance in­vestors smile as frown lines drug suc­ceeds piv­otal ...

7 years ago
News Briefing

Van­da's PhII da­ta of­fer hope for gas­tro­pare­sis pa­tients who have seen no new treat­ments in decades

7 years ago
R&D

No­var­tis plots to re­tain hives pa­tients with mon­o­clon­al an­ti­body that out­shines Xo­lair

7 years ago
R&D

Armed with up­dat­ed 24-week PhI­II da­ta, GBT con­vinces FDA to re­view sick­le cell drug un­der ac­cel­er­at­ed path­way

7 years ago
R&D

Red­Hill's an­tibi­ot­ic Tal­i­cia edges clos­er to ap­proval, af­ter sec­ond suc­cess­ful Phase III study

7 years ago
R&D

Fi­nal­ly sat­is­fied with Oc­u­lar's man­u­fac­tur­ing set­up, FDA ap­proves eye drug/de­vice Dex­ten­za

7 years ago
Pharma

Spot­light on drug pric­ing could be cat­a­lyst for change in US biosim­i­lar land­scape

7 years ago
R&D
Pharma

Lund­beck­'s Dun­sire has some­thing to cheer as Rex­ul­ti com­bo shows promise in PTSD

7 years ago
R&D
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times